We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Alicia Morgans

Alicia K. Morgans MD, MPH

Genitourinary Medical Oncologist, Dana-Farber Cancer Institute, Boston, Massachusetts

Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts. She specializes is investigating complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications.  She also serves as the Principal Investigator for multiple prostate cancer clinical trials, including the ECOG Phase 3 ERADICATE trial. She is a member of the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and is a member of the cardio-oncology committee of American Heart Association.  She is the President of the Medical Advisory Board and the Vice Chair of the Board of Directors of ZERO.

Disclosures

Dr. Morgans reports the following:
  • Consulting honoraria:  Astellas, AstraZeneca, AAA, Bayer, Clovis, Dendreon, Lantheus, Myovant, Pfizer, Merck, Novartis, Sanofi, Seattle Genetics
  • Research collaborations support:  Bayer, Myovant, Astellas, Seattle Genetics, Sanofi